Dr. Laurent  Desaubry
My Social Links

Dr. Laurent Desaubry

Research Director
University of Strasbourg, France


Highest Degree
Ph.D. in Medicinal Chemistry from Louis Pasteur University, France

Share this Profile

Biography

Dr. Laurent Desaubry is currently working as CNRS Research Director at Laboratory of Therapeutic Innovation, France. He has completed his Ph.D. in Medicinal Chemistry from Louis Pasteur University, France. He also appointed as Postdoctoral Associate in Pr Roger A. Johnson’s laboratory, Department of Physiology and Biophysics, State University of New York at Stony Brook, USA, laboratory of Pr Pierre Chambon and Dr Heinrich Gronemeyer at IGBMC, Strasbourg-Illkirch, Postdoctoral Associate and thereafter CNRS Research Senior Scientist (CR1) in the laboratory of Prs Guy Ourisson and Yoichi Nakatani in Louis Pasteur University, Strasbourg, and CNRS Senior Scientist (CR1) in the Laboratory of Therapeutic Innovation at Strasbourg Faculty of Pharmacy. He is member of editorial board in Frontiers in Chemistry, Medicinal Chemistry, Journal of Pharmaceutics and Modern Chemistry. He is member of American Chemical Society (ACS), and European Association for Cancer Research (EACR). His main area of expertise includes Medicinal Chemistry, Cardio protection, Organic Chemistry, Cytoprotection, Cancer, and Stem cells. He has 56 publications in journals as author/co-author.

Area of Interest:

Chemistry
100%
Medicinal Chemistry
62%
Organic Synthesis
90%
Bioorganic Chemistry
75%
Organic Chemistry
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Yuan, G., X. Chen, Z. Liu, W. Wei and Q. Shu et al., 2018. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway. J. Exp. Clin. Cancer Res., Vol. 37. 10.1186/s13046-018-0695-5.
    CrossRef  |  Direct Link  |  
  2. Tabet, R., L. Schaeffer, F. Freyermuth, M. Jambeau and M. Workman et al., 2018. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat. Commun., Vol. 9. 10.1038/s41467-017-02643-5.
    CrossRef  |  Direct Link  |  
  3. Sfakianos, A.P., L.E. Mellor, Y.F. Pang, P. Kritsiligkou and H. Needs et al., 2018. The mTOR-S6 kinase pathway promotes stress granule assembly. Cell Death Differ. 10.1038/s41418-018-0076-9.
    CrossRef  |  Direct Link  |  
  4. Abou-Hamdan, H. and L. Desaubry, 2018. Scalable 9-step synthesis of the splicing modulator NVS-SM2. J. Org. Chem., 83: 2954-2958.
    CrossRef  |  Direct Link  |  
  5. Yurugi, H., F. Marini, C. Weber, K. David and Q. Zhao et al., 2017. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene, 36: 4778-4789.
    CrossRef  |  Direct Link  |  
  6. Malka-Mahieu, H., M. Newman, L. Desaubry, C. Robert and S. Vagner, 2017. Molecular pathways: The eIF4F translation initiation complex-new opportunities for cancer treatment. Clin. Cancer Res., 23: 21-25.
    CrossRef  |  Direct Link  |  
  7. Emhemmed, F., S.A. Azouaou, Q. Zhao, A. Appert-Collin and A. Bennasroune et al., 2017. Pro-differentiating effects of a synthetic flavagline on human teratocarcinomal cancer stem-like cells. Cell Biol. Toxicol., 33: 295-306.
    CrossRef  |  Direct Link  |  
  8. Zhao, Q., H. Abou-Hamdan and L. Desaubry, 2016. Recent advances in the synthesis of flavaglines, a family of potent bioactive natural compounds originating from traditional Chinese medicine. Eur. J. Org. Chem., 36: 5908-5916.
    CrossRef  |  Direct Link  |  
  9. Zhao, Q., A. Tijeras-Raballand, A. de Gramont, E. Raymond and L. Desaubry, 2016. Bioisosteric modification of flavaglines. Tetrahedron Lett., 57: 2943-2944.
    CrossRef  |  Direct Link  |  
  10. Wang, S., C. Darini, L. Desaubry and A.E. Koromilas, 2016. STAT1 promotes KRAS colon tumor growth and susceptibility to pharmacological inhibition of translation initiation factor eIF4A. Mol. Cancer Therapeut., 15: 3055-3063.
    CrossRef  |  Direct Link  |  
  11. Wang, D., J. Zhao, Y. Wang, J. Hu and L. Li et al., 2016. A general and efficient synthesis of 2-pyridones, 2-quinolinones and 1-isoquinolinones from azine N-oxides. Asian J. Org. Chem., 5: 1442-1446.
    CrossRef  |  Direct Link  |  
  12. Nebigil, C.G., N. Tounsi, G. Fuhrmann and L. Desaubry, 2016. Quo vadis, cardio-oncology? Adv. Oncol. Res. Treat., Vol. 1. .
    Direct Link  |  
  13. Malka-Mahieu, H., I. Girault, M. Rubington, M. Leriche and C. Welsch et al., 2016. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Cell Cycle, 15: 2405-2409.
    CrossRef  |  Direct Link  |  
  14. Han, J., Q. Zhao, C. Basmadjian, L. Desaubry and A.L. Theiss, 2016. Flavaglines ameliorate experimental colitis and protect against intestinal epithelial cell apoptosis and mitochondrial dysfunction. Inflamm. Bowel Dis., 22: 55-67.
    CrossRef  |  Direct Link  |  
  15. Hammoud, H., Q. Zhao and L. Desaubry, 2016. Synthesis of hydroxybenzofurans by condensation of quinones with benzoylacetone: Revised structure of the adducts. Tetrahedron Lett., 57: 4044-4045.
    CrossRef  |  Direct Link  |  
  16. Wintachai, P., F. Thuaud, C. Basmadjian, S. Ubol, L. Desaubry and D.R. Smith, 2015. Assessment of flavaglines as potential chikungunya virus entry inhibitors. Microbiol. Immuno., 59: 121-141.
    CrossRef  |  Direct Link  |  
  17. Qureshi, R., O. Yildirim, A. Gasser, C. Basmadjian and Q. Zhao et al., 2015. FL3, a synthetic flavagline and ligand of prohibitins, protects cardiomyocytes via STAT3 from doxorubicin toxicity. PLoS ONE, Vol. 10. 10.1371/journal.pone.0141826.
    CrossRef  |  Direct Link  |  
  18. Gasser, A., S. Brogi, K. Urayama, T. Nishi and H. Kurose et al., 2015. Discovery and cardioprotective effects of the first non-peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS ONE, Vol. 10. 10.1371/journal.pone.0121027.
    CrossRef  |  Direct Link  |  
  19. Blanchard, M.G., J.H.F. de Baaij, S.A.J. Verkaart, A.L. Lameris and C. Basmadjian et al., 2015. Flavaglines stimulate Transient Receptor Potential Melastatin type 6 (TRPM6) channel activity. PLoS ONE, Vol. 10. 10.1371/journal.pone.0119028.
    CrossRef  |  Direct Link  |  
  20. Basmadjian, C., H. Malka-Mahieu and L. Desaubry, 2015. Revision of the synthesis and pharmacological activity of a reported translation inhibitor. Anti-Cancer Agents Med. Chem., 15: 1305-1307.
    CrossRef  |  Direct Link  |  
  21. Basmadjian, C., F. Zhang and L. Desaubry, 2015. Novel carbocationic rearrangements of 1-styrylpropargyl alcohols. Beilstein J. Org. Chem., 11: 1017-1022.
    CrossRef  |  Direct Link  |  
  22. Basmadjian C., G. Zhao and L. Desaubry, 2015. Exploratory studies toward a synthesis of flavaglines. A novel access to a highly substituted cyclopentenone intermediate. Tetrahedron Lett., 56: 727-730.
    CrossRef  |  Direct Link  |  
  23. Salome, C.; N. Ribeiro, C. Chavagnan, F. Thuaud and M. Serova et al., 2014. Benzofuran derivatives as anticancer agents. Eur. J. Med. Chem., 74: 181-191.
  24. Salome, C., V. Narbonne, N. Ribeiro, F. Thuaud, M. Serova and A.A. Gramont et al., 2014. Benzofuran derivatives as a novel class of inhibitors of mTOR signaling. Eur. J. Med. Chem., 74: 41-49.
    CrossRef  |  Direct Link  |  
  25. Nakatani, Y., N. Ribeiro, S. Streiff, M. Gotoh, G. Pozzi, L. Desaubry and A. Milon, 2014. Search for the most 'primitive' membranes and their reinforcers: a review of the polyprenyl phosphates theory. Orig. Life Evol. Biosph., 44: 197-208.
    CrossRef  |  Direct Link  |  
  26. Emhemmed F., S.A. Azouaou, F. Thuaud, V. Schini-Kerth, L. Desaubry, C. Muller and G. Fuhrmann, 2014. Selective anticancer effects of a synthetic flavagline on human Oct-4 expressing cancer stem-like cells via a p38 MAPK-dependent caspase 3-dependent pathway. Biochem. Pharmacol., 89: 185-196.
    CrossRef  |  Direct Link  |  
  27. Thuaud, F., N. Ribeiro, C.G. Nebigil and L. Desaubry, 2013. Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chem. Biol., 20: 316-331.
    CrossRef  |  Direct Link  |  
  28. Basmadjian, C., F. Thuaud, N. Ribeiro and L. Desaubry, 2013. Flavaglines: potent anticancer drugs that target prohibitins and the eIF4 helicase. Future Med. Chem., 5: 2185-2197.
    CrossRef  |  Direct Link  |  
  29. Aubert, M., F. Thuaud, N. Ribeiro, L. Desaubry and E. Espinosa, 2013. N-[3a-(4-Bromophenyl)-8b-hydroxy-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta[b ]benzofuran-1-yl]formamide monohydrate. Acta Cryst., 69: 52-53.
    Direct Link  |  
  30. Ribeiro, N., F. Thuaud, Y. Bernard, C. Gaiddon and T. Cresteil et al., 2012. Flavaglines as potent anticancer and cytoprotective agents. J. Med. Chem., 55: 10064-10073.
    Direct Link  |  
  31. Ribeiro, N., F. Thuaud, C. Nebigil and L. Desaubry, 2012. Recent advances in the biology and chemistry of the flavaglines. Bioorg. Med. Chem., 21: 1857-1864.
    CrossRef  |  Direct Link  |  
  32. Polier, G., J. Neumann, F. Thuaud, N. Ribeiro and C. Gelhaus et al., 2012. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol., 19: 1093-1104.
    CrossRef  |  Direct Link  |  
  33. Nakatani, Y., N. Ribeiro, S. Streiff, L. Desaubry and G. Ourisson, 2012. Search for the most primitive membranes: some remaining problems. Orig. Life Evol. Biosph., 42: 497-501.
    CrossRef  |  Direct Link  |  
  34. Heitz, T., E. Widemann , R. Lugan, L. Miesch and P. Ullmann et al., 2012. Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of the plant hormone jasmonoyl-isoleucine for catabolic turnover. J. Biol. Chem., 287: 6296-6306.
    CrossRef  |  Direct Link  |  
  35. Thuaud, F., N. Ribeiro, C. Gaiddon, T. Cresteil and L. Desaubry, 2011. Novel flavaglines displaying improved cytotoxicity. J. Med. Chem., 54: 411-415.
    CrossRef  |  Direct Link  |  
  36. Polier, G, J. Ding, B.V. Konkimalla, D. Eick and N. Ribeiro et al., 2011. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell. Death Dis., 2: 182-182.
    CrossRef  |  Direct Link  |  
  37. Bernard, Y., N. Ribeiro, F. Thuaud, G. Turkeri and R. Dirr et al., 2011. Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLos One, 6: e25302-e25302.
    CrossRef  |  Direct Link  |  
  38. Thuaud F., Y. Bernard,G. Turkeri, R. Dirr and G. Aubert et al., 2009. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12. J. Med. Chem., 52: 5176-5187.
    CrossRef  |  Direct Link  |  
  39. Mekideche, S. and L. Desaubry, 2008. Tandem Diels-Alder-manganese dioxide mediated oxidation reaction. A short route to marcanines. Tetrahedron Lett., 49: 5268-5270.
    CrossRef  |  Direct Link  |  
  40. Dirr, R., C. Antheaume and L. Desaubry, 2008. Regioselectivity of fluorine substitution by alkoxides on unsymmetrical difluoroarenes. Tetrahedron Lett., 49: 4588-4590.
    CrossRef  |  Direct Link  |  
  41. Desaubry, L., S. Riche, P. Laeuffer and J.P. Cazenave, 2008. Synthesis and biological evaluation of PEG-tirofiban conjugates. Bioorg. Med. Chem. Lett., 18: 2028-2031.
    CrossRef  |  Direct Link  |  
  42. Ribeiro, N., S. Streiff, D. Heissler, M. Elhabiri and A.M. Albrecht-Gary et al., 2007. Reinforcing effect of bi- and tri-cyclopolyprenols on primitive membranes made of polyprenyl phosphates. Tetrahedron, 63: 3395-3407.
    CrossRef  |  Direct Link  |  
  43. Ribeiro, N., H. Tabaka, J. Peluso, L. Fetzer and C. Nebigil et al., 2007. Synthesis of 3-O-methylviridicatin analogues with improved anti-TNF-α properties. Bioorg. Med. Chem. Lett., 17: 5523-5524.
    CrossRef  |  Direct Link  |  
  44. Compain, P., V. Desvergnes, C. Ollivier, F. Robert and F. Suzenet et al., 2006. Alchimies futures : compte rendu de l'experience ESYOP. Comptes Rendus Chimie, 9: 127-140.
    CrossRef  |  Direct Link  |  
  45. Sani Souna, S.A., L. Boulenger and L. Desaubry, 2005. Palladium catalysed arylation of 6,8-dimethoxybenzofuranone. Tetrahedron Lett., 46: 8017-8018.
    CrossRef  |  Direct Link  |  
  46. Brisach-Wittmeyer, A., A.S. Souna Sido, P. Guilini and L. Desaubry, 2005. Concise synthesis and voltammetric studies of dielsiquinone, a cytotoxic azaanthraquinone. Bioorg. Med. Chem. Lett., 15: 3609-3610.
    CrossRef  |  Direct Link  |  
  47. Streiff, S., N. Ribeiro and L. Desaubry, 2004. Unexpected cleavage of tetrahydrofuran by catalytic reductive lithiation. Chem. Commun., 10.1039/B312972A .
    CrossRef  |  Direct Link  |  
  48. Streiff, S., N. Ribeiro and L. Desaubry, 2004. Synthesis of allylsilanes by reductive lithiation of thioethers. J. Org. Chem., 69: 7592-7598.
    CrossRef  |  Direct Link  |  
  49. Sedaghat, S., L. Desaubry, S. Streiff, N. Ribeiro, B. Michels, Y. Nakatani and G. Ourisson, 2004. A novel type of membranes based on cholesteryl phosphate. Chem. Biodivers., 1: 124-128.
    CrossRef  |  Direct Link  |  
  50. Raboisson, P., C. Lugnier, C. Muller, J.M. Reimund and D. Schultz et al., 2003. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors. Eur J. Med. Chem. 38: 199-214.
    CrossRef  |  Direct Link  |  
  51. Desaubry, L., Y. Nakatani and G. Ourisson, 2003. Toward higher polyprenols under prebiotic conditions. Tetrahedron Lett., 44: 6959-6961.
    CrossRef  |  Direct Link  |  
  52. Lee, S., L. Desaubry, Y. Nakatani and G. Ourisson, 2002. Vectorial properties of small vesicles. C.R. Acad. Sci. Chimie, 5: 331-335.
    CrossRef  |  Direct Link  |  
  53. Shoshani, I., G. Bianchi, L. Desaubry, C.W. Dessauer and R.A. Johnson, 2000. Lys-Ala mutations of type I adenylyl cyclase result in altered susceptibility to inhibition by adenine nucleoside 3'-polyphosphates. Arch. Biochem. Biophys., 374: 389-394.
    CrossRef  |  Direct Link  |